- In June 2024, BIOMÉRIEUX received FDA approval for its BIOFIRE SPOTFIRE Respiratory/Sore Throat, a point-of-care (POC) platform
- In May 2024, Cipla entered into an agreement to invest in Achira Labs Private Limited, a company responsible for the commercialization of point-of-care test kits in India
- In May 2023, bioMérieux obtained the US FDA CLIA-waiver for the BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, a multiplex PCR-based test approved for use on the BIOFIRE SPOTFIRE System
- In August 2023, BD received US FDA approval for its BD Respiratory Viral Panel (RVP) for the BD MAX System, a molecular diagnostic test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in approximately 2 hours
- In March 2023, bioLytical Laboratories Inc. received Health Canada approval for its INSTI Multiplex HIV-1/2 Syphilis Antibody Test
- In December 2023, Thermo Fisher Scientific Inc. partnered with Project HOPE, a leading global health organization, to expand the accessibility of HIV diagnostic services for HIV-positive youth in Sub-Saharan Africa
